||Rudolph A, Hein R, LindstrÃ¶m S, Beckmann L, Behrens S, Liu J, Aschard H, Wang J, Truong T, Cordina-Duverger E, Menegaux F, Severi G, Baglietto L, Southey M, Chanock SJ, Lissowska J, Figueroa JD, Eriksson M, Humpreys K, Darabi H, Olson JE, Stevens KN, Vachon CM, Knight JA, Glendon G, Mulligan AM, Ashworth A, Orr N, Schoemaker M, GuÃ©nel P, Brauch H, Giles G, GarcÃa-Closas M, Czene K, Couch FJ, Andrulis IL, Swerdlow A, Hunter DJ, Flesch-Janys D, Hall P, Nevanlinna H, Kraft P, Chang-Claude J, Breast Cancer Association Consortium
||Women using menopausal hormone therapy (MHT) are at increased risk of developing breast cancer (BC). To detect genetic modifiers of the association between current use of MHT and BC risk, we conducted a meta-analysis of four genome-wide case-only studies followed by replication in 11 case-control studies. We used a case-only design to assess interactions between single-nucleotide polymorphisms (SNPs) and current MHT use on risk of overall and lobular BC. The discovery stage included 2920 cases (541 lobular) from four genome-wide association studies. The top 1391 SNPs showing P values for interaction (Pint) <3.0 Ã 10(-3) were selected for replication using pooled case-control data from 11 studies of the Breast Cancer Association Consortium, including 7689 cases (676 lobular) and 9266 controls. Fixed-effects meta-analysis was used to derive combined Pint. No SNP reached genome-wide significance in either the discovery or combined stage. We observed effect modification of current MHT use on overall BC risk by two SNPs on chr13 near POMP (combined Pintâ¤8.9 Ã 10(-6)), two SNPs in SLC25A21 (combined Pintâ¤4.8 Ã 10(-5)), and three SNPs in PLCG2 (combined Pintâ¤4.5 Ã 10(-5)). The association between lobular BC risk was potentially modified by one SNP in TMEFF2 (combined Pintâ¤2.7 Ã 10(-5)), one SNP in CD80 (combined Pintâ¤8.2 Ã 10(-6)), three SNPs on chr17 near TMEM132E (combined Pintâ¤2.2Ã10(-6)), and two SNPs on chr18 near SLC25A52 (combined Pintâ¤4.6 Ã 10(-5)). In conclusion, polymorphisms in genes related to solute transportation in mitochondria, transmembrane signaling, and immune cell activation are potentially modifying BC risk associated with current use of MHT. These findings warrant replication in independent studies.